<i>In Vitro</i> Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of <i>Enterobacterales</i> , Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018
Yang Yang, Yan Guo, Dandan Yin, Yonggui Zheng, Shi Wu, Demei Zhu, Fupin Hu
Abstract
This study evaluated the in vitro activity of cefepime-zidebactam in comparison with that of ceftazidime-avibactam and other comparators against clinically significant Gram-negative bacillus isolates. A total of 3,400 nonduplicate Gram-negative clinical isolates were collected from 45 medical centers across China in the CHINET Program in 2018, including Enterobacterales ( n = 2,228), Pseudomonas aeruginosa ( n = 657), and Acinetobacter baumannii ( n = 515).
Topics & Concepts
Ceftazidime/avibactamAcinetobacter baumanniiCefepimePseudomonas aeruginosaMicrobiologyCeftazidimeAntimicrobialAcinetobacterBiologyKlebsiella pneumoniaeAntibioticsBacteriaEscherichia coliBiochemistryGeneticsGeneAntibiotic Resistance in BacteriaAntibiotic Use and ResistancePharmaceutical and Antibiotic Environmental Impacts